Wegovy

America’s obesity epidemic is at a crossroads.

Wegovy is now approved in the U.S. as the first therapy to help people manage their weight and reduce cardiovascular risk.

The popular weight loss drug gets FDA approval to reduce risk of heart attack and stroke in obese and overweight adults who don’t have diabetes.

Plaintiffs claim they suffered from gastroparesis, a condition in which an individual’s stomach fails to properly empty, after taking drugs like Ozempic.

The FDA is also investigating reported side effects of aspiration.

While Ozempic, Wegovy, and Mounjaro have gained attention for their significant weight loss effects, the drugs’ domestic cost has raised some eyebrows.

Hospitalized people suffered diabetic shock and coma, suggesting the pens contained insulin instead of the ingredient semaglutide.

Criminals have begun selling fake products following a spike in demand and resultant shortage of products.

While Ozempic captures headlines, traditional herbs and spices present compelling alternatives for metabolic health.

Weight-loss drugs such as Wegovy and Ozempic may increase rare risks of pancreatitis, bowel obstruction, and gastroparesis.

The FDA has, thus far, received 14,149 adverse events reports for Ozempic, out of which, 6,253 were ‘serious cases,’ including 163 deaths.

Over half of the adverse event reports by the FDA describe suicidal thoughts arising soon after starting or ramping up doses of these injectable drugs.

Ozempic and Wegovy may help people lose weight but are associated with a long list of very serious side effects.